{"classes":[{"categories":[{"measurements":[{"comment":"Geometric Mean (Geometric Coefficient of Variation) is not calculable for a single participant.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Geometric Mean (Geometric Coefficient of Variation) is not calculable for a single participant.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Geometric Mean (Geometric Coefficient of Variation) is not calculable for a single participant.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"67.5","value":"151"},{"groupId":"OG004","spread":"104","value":"170"},{"groupId":"OG005","spread":"72.7","value":"268"},{"groupId":"OG006","spread":"46.4","value":"341"},{"groupId":"OG007","spread":"0","value":"0"},{"groupId":"OG008","spread":"77.8","value":"352"},{"groupId":"OG009","spread":"133","value":"123"},{"groupId":"OG010","spread":"39","value":"84.5"},{"groupId":"OG011","spread":"53.8","value":"165"},{"groupId":"OG012","spread":"77.8","value":"248"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"22"}],"units":"Participants"}],"description":"Blood samples will be taken to measure the plasma concentrations of BDTX-189 in both a fed and fasted state.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients who received doses at 25 mg once daily under fasted conditions.","id":"OG000","title":"Dose Escalation 25 mg QD"},{"description":"Patients who received doses at 50 mg once daily under fasted conditions.","id":"OG001","title":"Dose Escalation 50 mg QD"},{"description":"Patients who received doses at 100 mg once daily under fasted conditions.","id":"OG002","title":"Dose Escalation 100 mg QD"},{"description":"Patients who received doses at 200 mg once daily under fasted conditions.","id":"OG003","title":"Dose Escalation 200 mg QD"},{"description":"Patients who received 400 mg once daily under fasted conditions.","id":"OG004","title":"Dose Escalation 400 mg QD"},{"description":"Patients who received 800 mg once daily under fasted conditions.","id":"OG005","title":"Dose Escalation 800 mg QD"},{"description":"Patients who received 800 mg once daily under not fasted conditions.","id":"OG006","title":"Dose Escalation 800 mg QD NF"},{"description":"Patients who received 1000 mg once daily under not fasted conditions","id":"OG007","title":"Dose Escalation 1000 mg QD"},{"description":"Patients who received 1200 mg once daily under fasted conditions.","id":"OG008","title":"Dose Escalation 1200 mg QD"},{"description":"Patients who received 400 mg twice daily under not fasted conditions.","id":"OG009","title":"Dose Escalation 400 mg BID"},{"description":"Patients who received 600 mg twice daily under not fasted conditions.","id":"OG010","title":"Dose Escalation 600 mg BID"},{"description":"Patients who received 800 mg twice daily under fasted conditions.","id":"OG011","title":"Dose Escalation 800 mg BID"},{"description":"Patients in safety expansion who received 800 mg once daily under not fasted conditions.","id":"OG012","title":"Safety Expansion 800 mg QD"}],"paramType":"GEOMETRIC_MEAN","reportingStatus":"POSTED","timeFrame":"Multiple time points during Cycles 1-4 (each cycle is 21 days)","title":"Phase 1: Plasma Concentration of BDTX-189 as a Measure of Pharmacokinetics","type":"SECONDARY","unitOfMeasure":"Nanogram per mililiter (ng/mL)"}